Antagonist targeting microRNA-155 protects against lithium-pilocarpine-induced status epilepticus in C57BL/6 mice by activating brain-derived neurotrophic factor

Antagonist targeting microRNA-155 protects against lithium-pilocarpine-induced status epilepticus in C57BL/6 mice by activating brain-derived neurotrophic factor

Blog Article

Epilepsy is a severe brain disorder affecting numerous patients.Recently, it is inferred that modulation of microRNA-155 (miR-155) could serve as a promising treatment of mesial temporal lobe epilepsy (MTLE).In the current study, the therapeutic potential of miR-155 antagonist against TLE was evaluated and the underlying mechanism involved in this regulation was explored.TLE model was induced by lithium-pilocarpine method.

The effect of miR-155 antagonist on epilepticus symptoms of TLE mice was assessed using Racine classification and electroencephalogram (EEG) recordings.The expression of brain-derived neurotrophic factor (BDNF) and its association g5210t-p90 with miR-155 were also assessed with a series of experiments.Our results showed that level of miR-155 was significantly up-regulated after induction of TLE model.Based on the results of EEG and behavior analyses, seizures in mice were alleviated by miR-155 antagonist.

Moreover, administration of miR-155 antagonist also significantly increased the level of BDNF.The results of dual luciferase assay and western blotting showed that miR-155 antagonist exerted its action on status epilepticus by directly regulating the activity of BDNF.Taken all the information together, our results demonstrated that miR-155 antagonist might read more firstly induce the expression of BDNF, which then contributed to the alleviation of epilepsy in the current study.